Webcast ImageWebcast
Q4 2016 Clovis Oncology, Inc. Earnings Conference Call (Replay)
02/22/17 at 4:30 p.m. ET
Q4 2016 Clovis Oncology, Inc. Earnings Conference Call
Wednesday, February 22, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 0.19 (0.33%)
Intraday High$59.33
Intraday Low$56.56
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
02/22/17Clovis Oncology Announces 2016 Operating Results
Rubraca™ (rucaparib) approved and launched in the U.S. on December 19, 2016 for the treatment of advanced BRCA-mutant ovarian cancer $266.2M in cash, cash equivalents and available for sale securities at December 31, 2016 $487.4M in adjusted cash, cash equivalents and available for sale securities at December 31, 2016 as adjusted for the January 2017 financing proceeds of $221.2 million ... 
Printer Friendly VersionDownload PDF
02/09/17Clovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 9, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the ... 
Printer Friendly VersionDownload PDF
02/01/17Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program
Strata Trial to Identify Genetically Selected Patients Eligible for Enrollment in Clovis’ TRITON Studies in Advanced Prostate Cancer BOULDER, Colo. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Feb. 1, 2017-- Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.